Keros Therapeutics (NASDAQ:KROS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13), Briefing.com reports. The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.33) earnings per share.
Keros Therapeutics Price Performance
Shares of KROS stock opened at $67.99 on Friday. The firm’s 50-day moving average is $57.30 and its two-hundred day moving average is $51.99. The company has a market capitalization of $2.55 billion, a PE ratio of -13.09 and a beta of 1.23. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on KROS shares. Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating on the stock. Guggenheim initiated coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Scotiabank initiated coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday. Finally, Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $88.89.
Insider Activity
In other news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 22.90% of the company’s stock.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
- Five stocks we like better than Keros Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- The Top 5 Performing S&P 500 Stocks YTD in 2024
- Upcoming IPO Stock Lockup Period, Explained
- L3Harris: Positioned for Gains With Trump’s Defense Policies
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Is First Solar’s Earnings Drop a Golden Buying Opportunity?
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.